Insider · CIK 0001359089

Joshi Abhay

Reports to the SEC for 2 companies · NEWARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001359089

Forms 4 and 5

Insider transactions

41 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2022-03-15	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−2,607 sh	$15.79	−$41.2K	120,708
2022-02-15	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−2,151 sh	$13.35	−$28.7K	126,217
2022-02-15	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−2,902 sh	$13.35	−$38.7K	123,315
2021-03-15	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−1,354 sh	$27.73	−$37.5K	128,368
2021-02-15	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−1,967 sh	$28.97	−$57K	132,603
2021-02-15	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−2,881 sh	$28.97	−$83.5K	129,722
2021-02-02	Revance Therapeutics, Inc.A Award	COO, President of R&D	AAward	+22.6K sh	—	—	134,570
2021-02-02	Revance Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	COO, President of R&D	AAward	+40.9K sh	—	—	40,925
2020-09-30	Revance Therapeutics, Inc.A Award	COO, President of R&D	AAward	+17.5K sh	—	—	119,332
2020-09-30	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−7,382 sh	$25.14	−$186K	111,950
2020-03-15	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−1,354 sh	$15.50	−$21K	101,832
2020-02-15	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−3,325 sh	$25.33	−$84.2K	103,186
2020-01-23	Revance Therapeutics, Inc.A Award	COO, President of R&D	AAward	+25K sh	—	—	106,511
2020-01-23	Revance Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	COO, President of R&D	AAward	+147K sh	—	—	146,500
2020-01-15	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−4,441 sh	$22.89	−$102K	81,511
2019-12-14	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−2,971 sh	$15.99	−$47.5K	85,952
2019-03-15	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−1,354 sh	$15.45	−$20.9K	88,923
2019-03-14	Revance Therapeutics, Inc.M Exercise/Conversion	COO, President of R&D	MExercise/Conversion	+666 sh	$4.20	+$2,797.2	90,443
2019-03-14	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−166 sh	$15.59	−$2,587.94	90,277
2019-03-14	Revance Therapeutics, Inc.Stock Option (Right to buy)M Exercise/Conversion	COO, President of R&D	MExercise/Conversion	−666 sh	—	—	0
2019-02-15	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−1,510 sh	$17.69	−$26.7K	89,777
2019-01-24	Revance Therapeutics, Inc.A Award	COO, President of R&D	AAward	+15.8K sh	—	—	91,287
2019-01-24	Revance Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	COO, President of R&D	AAward	+94K sh	—	—	94,000
2019-01-15	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−4,466 sh	$20.19	−$90.2K	75,537
2018-12-14	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−4,260 sh	$19.91	−$84.8K	80,003
2018-03-21	Revance Therapeutics, Inc.M Exercise/Conversion	COO, President of R&D	MExercise/Conversion	+666 sh	$2.55	+$1,698.3	84,263
2018-03-21	Revance Therapeutics, Inc.Stock Option (Right to buy)M Exercise/Conversion	COO, President of R&D	MExercise/Conversion	−666 sh	—	—	0
2018-02-15	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−1,509 sh	$31.75	−$47.9K	83,597
2018-02-08	Revance Therapeutics, Inc.A Award	COO, President of R&D	AAward	+11.8K sh	—	—	85,106
2018-02-08	Revance Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	COO, President of R&D	AAward	+70.5K sh	—	—	70,500
2018-01-15	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−4,327 sh	$34.50	−$149K	73,356
2017-12-14	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−3,229 sh	$32.15	−$104K	77,683
2017-01-26	Revance Therapeutics, Inc.A Award	COO, President of R&D	AAward	+13.1K sh	—	—	80,912
2017-01-26	Revance Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	COO, President of R&D	AAward	+79K sh	—	—	79,000
2016-12-15	Revance Therapeutics, Inc.A Award	COO, President of R&D	AAward	+36K sh	—	—	67,812
2016-12-14	Revance Therapeutics, Inc.F Tax Payment	COO, President of R&D	FTax Payment	−3,229 sh	$16.70	−$53.9K	31,812
2016-08-12	Revance Therapeutics, Inc.M Exercise/Conversion	COO, President of R&D	MExercise/Conversion	+666 sh	$6.60	+$4,395.6	35,041
2016-08-12	Revance Therapeutics, Inc.Stock Option (Right to buy)M Exercise/Conversion	COO, President of R&D	MExercise/Conversion	−666 sh	—	—	0
2015-12-14	Revance Therapeutics, Inc.A Award	COO, President of R&D	AAward	+34.4K sh	—	—	34,375
2015-12-14	Revance Therapeutics, Inc.Stock Option (Right to buy)A Award	COO, President of R&D	AAward	+206K sh	—	—	206,250
2006-06-30	COTHERIX INCStock Option (Right to Buy)A Award	EVP, Chief Technical Officer	AAward	+50K sh	—	—	50,000

Recent filings

Accepted (ET)
Mar 174
Joshi Abhay0001209191-22-019727
SEC(opens sec.gov)
Feb 174
Joshi Abhay0001479290-22-000023
SEC(opens sec.gov)
Mar 174
Joshi Abhay0001479290-21-000081
SEC(opens sec.gov)
Feb 194
Joshi Abhay0001479290-21-000043
SEC(opens sec.gov)
Feb 44
Joshi Abhay0001479290-21-000037
SEC(opens sec.gov)
Oct 24
Joshi Abhay0001628280-20-014240
SEC(opens sec.gov)
Mar 174
Joshi Abhay0001209191-20-019835
SEC(opens sec.gov)
Feb 194
Joshi Abhay0001479290-20-000032
SEC(opens sec.gov)
Jan 244
Joshi Abhay0001479290-20-000015
SEC(opens sec.gov)
Jan 174
Joshi Abhay0001479290-20-000010
SEC(opens sec.gov)
Dec 174
Joshi Abhay0001479290-19-000113
SEC(opens sec.gov)
Mar 184
Joshi Abhay0001479290-19-000034
SEC(opens sec.gov)

Companies

Address

C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD

NEWARK, CA, 94560